IBIrina E. Baykova

Irina E. Baykova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irina E. Baykova has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Follistatin-Like Protein 1 and Cardiovascular Diseases

    by A. M. Alieva, I. E. Baykova, A. B. Sultangalieva, I. G. Nikitin

    This literature review highlights the importance of assessing follistatin-like protein 1 levels for diagnostic and prognostic purposes. It is anticipated that future scientific and clinical studies will confirm the feasibility as an adjunct laboratory tool for diagnosis and prognosis evaluation in patients with cardiovascular diseases. Modulation of the concentration and expression of follistatin-like protein 1 may represent a promising therapeutic approach in the management of cardiovascular pathology.

  • Matrix metalloproteinase 2 as a biological marker in heart failure

    by A.M. Alieva, I.E. Baykova, N.KH. Khadzhieva, A.B. Sultangalieva, D.A. Elmurzaeva, A.M. Rakhaev, I.G. Nikitin

    Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.


  • Open Access

    A clinical case of ochronosis with involvement of the cardiac valvular apparatus and the musculoskeletal system in an 80-year-old patient

    by Amina M. Alieva, Irina V. Kovtyukh, Irina E. Baykova, Elvira A. Khachirova, Albina B. Sultangalieva, Alexander A. Melnikov, Igor G. Nikitin

    BACKGROUND: Ochronosis is a rare disorder caused by an inherited defect in tyrosine metabolism, in which the biochemical degradation pathway is interrupted at the stage of homogentisic acid formation. The clinical manifestations of the disease include homogentisic aciduria (presenting in infancy), gradual development of ochronosis after 20–30 years of age, and degenerative ochronotic arthropathy, typically occurring in the fourth decade of life. In addition, involvement of the cardiovascular system and the urinary tract may be observed. Management of ochronosis requires a comprehensive approach that includes both pharmacological and non-pharmacological interventions. Reports of clinical cases of ochronosis in the Russian scientific data remain limited. CASE DESCRIPTION: This article presents a clinical case of ochronosis with involvement of the cardiac valvular apparatus and the musculoskeletal system in an 80-year-old woman with a history of comorbidities. Musculoskeletal condition had been present since 2007. Pronounced cutaneous manifestations appeared in 2023 (pigmentation changes of the auricles, cheeks, and sclerae). The patient underwent multiple surgical interventions for musculoskeletal disorders. In 2023, targeted laboratory investigations were performed for the first time to confirm ochronosis: 3-methylcrotonylglycine, 8.37 mmol/mol; homogentisic acid, 95.93 mmol/mol creatinine; and p-hydroxyphenyllactic acid, 6.24 mmol/mol creatinine, thereby confirming the diagnosis. Modern imaging and laboratory methods were key to the accurate diagnosis of this condition. CONCLUSION: Improving awareness of ochronosis among physicians of various specialties is essential for its early detection. Timely diagnosis of ochronosis enables initiation of treatment at earlier stages, which may reduce the risk of complications and improve patients’ quality of life.

  • Open Access

    ADAMTS-4 as cardiovascular biological marker in atherosclerosis (literature review)

    by Amina M. Alieva, Elena V. Reznik, Irina E. Bajkova, Natalia V. Teplova, Albina B. Sultangalieva, Elina Z. Etezova, Zhanna L. Rabaeva, Rugaya N. Imanova, Polina Yu. Boeva, Igor G. Nikitin, et al.

    Cardiovascular diseases are a serious problem for medicine, society and economy all over the world. Currently, there is an active search for new biological markers and therapeutic targets in order to develop effective approaches to risk stratification and secondary prevention of cardiovascular pathology. The range of scientific interests of researchers recently includes the study of disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) in atherosclerosis and related diseases. ADAMTS regulate the structure and function of extracellular matrix components. In our scientific review, we analyze current experimental and clinical studies devoted to the study of ADAMTS-4 as a new diagnostic and prognostic marker in atherosclerosis. The studies conducted to date indicate the important role of this biological marker in the pathogenesis and diagnosis of atherosclerosis. Future large-scale preclinical and clinical studies are expected to show that ADAMTS-4 may be a valuable addition to laboratory diagnostic methods. Regulation of ADAMTS-4 levels and expression may be an effective strategy for the treatment of patients with atherosclerosis.

  • Open Access

    Asprosin as a novel biological marker of atherosclerosis and carbohydrate metabolism disorders

    by Amina M. Alieva, Irina E. Baykova, Nyurzhanna Kh. Khadzhieva, Albina B. Sultangalieva, Alik M. Rakhaev, Dzhannet A. Elmurzaeva, Alim O. Asanov, Irina V. Kovtyukh, Elina Z. Etezova, Igor G. Nikitin, et al.

    Cardiovascular diseases represent a major global medical, social, and economic challenge. Active research is being conducted to identify new biological markers and therapeutic targets to develop effective approaches for risk stratification and secondary prevention of cardiovascular diseases. Despite the identification of numerous cardiovascular biomarkers, their translation into clinical practice has largely been unsuccessful. Recently, researchers have increasingly focused on asprosin. The primary objective of this article is to analyze existing studies on the role of asprosin as a biomarker in atherosclerosis and carbohydrate metabolism disorders. An increasing body of experimental evidence indicates that this biomarker contributes to the development and progression of atherosclerosis, diabetes mellitus, obesity, and polycystic ovary syndrome. Asprosin regulates various physiological processes, including appetite stimulation, glucose release, insulin secretion, apoptosis, and inflammation. Based on available clinical data, asprosin appears to be a promising molecule with both diagnostic and prognostic value in the context of atherosclerosis and carbohydrate metabolism disorders. Further research is needed to explore asprosin as an additional laboratory biomarker. Modulation of asprosin concentration and expression may become a promising therapeutic strategy for patients with atherosclerosis and carbohydrate metabolism disorders.

  • Open Access

    Myokines as biological markers in disorders of carbohydrate metabolism and atherosclerosis

    by A. M. Alieva, I. E. Baykova, M. F. Akhmedova, A. A. Melikulov, A. B. Sultangalieva, A. M. Rahaev, A. O. Asanov, A. A. Musukaev, I. G. Nikitin

    Cardiovascular diseases cause more than half of all deaths. Coronary heart disease is the leading cause of death worldwide. The main factor contributing to the development of coronary heart disease is atherosclerosis, which often does not show symptoms in the early stages. Carbohydrate metabolism disorders play an important role in the occurrence and worsening of cardiovascular diseases. The search for cardiovascular biomarkers that could help in the diagnosis of cardiovascular diseases and serve as prognostic indicators continues. This scientific review focuses on the importance of assessing myokines. To date, the significance of such myokines as myostatin, irisin, meteorin-like protein, brain-derived neurotrophic factor, apelin, mitsugumin 53 and others in cardiovascular pathology has been demonstrated. It has been established that myostatin negatively affects carbohydrate metabolism and atherosclerotic processes, worsening the lipid profile, increasing the accumulation of adipose tissue and reducing its “browning”. Suppression of myostatin in myocardial infarction promotes cardiac recovery; its concentrations, along with the level of troponin, reflect myocardial damage. Studies of the brain-derived neurotrophic factor also emphasize the importance and feasibility of its determination in diabetes mellitus and ischemic heart disease. Evaluation of the level of meteorin-like protein can be useful in diabetes mellitus and assessing the risk of atherosclerosis. A reliable relationship has been established between apelin and irisin with carbohydrate metabolism disorders and atherosclerotic cardiovascular diseases, which also makes them promising therapeutic molecules. Mitsugumin 53 has shown relevance as a marker in atherosclerosis, but its effect on carbohydrate metabolism requires clarification. Serial myokine testing, including the use of multimarker panels, requires further study to confirm its relevance in clinical practice.

  • The role of matrix metalloproteinase 9 as a biological marker in heart failure

    by Amina M. Alieva, Alik M. Rakhaev, Albina B. Sultangalieva, Irina E. Baykova, Aila M. Karakizova, Gayane G. Totolyan, Jannet A. Elmurzaeva, Makhty I. Akkiev, Linda A. Khachukaeva, Alim O. Asanov, et al.

    Heart failure (HF) is an important medical, social and economic problem. The study of new biological markers deepens our understanding of the pathogenesis of this disease. In modern cardiology, there is a growing interest in matrix metalloproteinases (MMPs). These enzymes play an important role in tissue remodeling, angiogenesis, as well as in cell proliferation, migration and differentiation. The purpose of this literature review is to analyze current experimental and clinical data on MMP-9 as a new diagnostic and prognostic marker in HF. This review presents an analysis of modern publications on a given topic. We conducted an analysis of literature sources covering all important materials as of 01.12.2024. Experimental studies have established that MMP-9 is a key participant in cardiac remodeling, since it is directly involved in the degradation of extracellular matrix proteins and the activation of profibrotic pathways, as well as cytokines and chemokines. Clinical trial data indicate the significant importance of MMP-9 for diagnosis and prognosis in patients with HF.

  • Chitinase-3-like protein 1 (CHI3L1, YKL-40) in cardiovascular pathology

    by A. M. Alieva, R. K. Valiev, I. E. Baykova, N. V. Teplova, L. M. Shnakhova, M. N. Saryev, I. A. Kotikova, I. G. Nikitin

    Cardiovascular diseases (CVD) represent a global medical, social, and economic issue. Currently, the search and study of new biological markers that can provide early diagnosis of CVD, serve as laboratory tools for assessing the effectiveness of treatment, or be used as prognostic markers and risk stratification criteria are ongoing. Scientists are particularly interested in studying chitinase-3-like protein 1 (CHI3L1, YKL-40) in relation to CVD. The precise role of CHI3L1 in both normal and pathological conditions remains unclear. Existing data suggest that CHI3L1 may regulate cell proliferation, differentiation, programmed cell death, as well as participate in embryonic development, angiogenesis, inflammatory responses, tissue remodeling, and a number of other processes. According to clinical studies conducted, CHI3L1 is a promising molecule with diagnostic and prognostic potential in CVD. The definitive confirmation of the role of CHI3L1 in cardiovascular pathology will be obtained through future research.

  • Open Access

    LOX-1 as a biological marker and therapeutic target in cardiovascular pathology (literature review)

    by Amina M. Alieva, Irina E. Baykova, Elena V. Reznik, Natalia V. Teplova, Ramiz K. Valiev, Malika Kh. Gyzyeva, Albina B. Sultangalieva, Irina A. Kotikova, Natalia A. Novikova, Sergey A. Korvyakov, et al.

    Cardiovascular diseases (CVD) are a global medical, social and economic problem. Currently, the search and study of new biological markers that can provide early diagnosis of CVD, serve as a laboratory tool for evaluating the effectiveness of treatment or be used as prognostic markers and criteria for risk stratification continues. The interest of scientists is focused on the study of the type 1 lectin-like receptor for oxidized low-density lipoproteins (LOX-1) as a diagnostic and prognostic marker in CVD. The presented literature review highlights the potential significance of the LOX-1 study as a diagnostic and prognostic laboratory tool in CVD. It is expected that future clinical and experimental studies will confirm the possibility of using LOX-1 as an additional non-invasive tool for diagnosis and prognosis assessment in patients with CVD. Modulation of LOX-1 levels and expression using pharmacological drugs may prove to be a promising direction for the treatment of CVD.


  • Open Access

    Prospects of using miRNA-378 as a biomarker for cardiovascular diseases: A literature review

    by Amina M. Alieva, Nyurzhanna Kh. Khadzhieva, Irina E. Baykova, Alik M. Rakhaev, Irina A. Kotikova, Igor G. Nikitin, Хаджиева Нюржанна Хусейновна

    Currently, there is an active search for new biomarkers and therapeutic targets to develop effective approaches to risk stratification and secondary prevention of cardiovascular diseases (CVD). Microribonucleic acids (miRNAs) are of particular interest to investigators. MiRNAs are endogenous small noncoding RNAs that regulate the transcription of factors that play a role in the proliferation, differentiation, cell growth, and tissue remodeling processes in CVD. MiRNA-378 is currently being analyzed as a biomarker for CVD. Thus, in this review, we aimed to describe the regulatory role of miRNA-378 and provide strong evidence for its feasibility as a biomarker. Further preclinical and clinical studies are required to identify the potential benefits of miRNA-378 as a biomarker in CVD.